Sven Undeland

Senior Consultant at FHC Undeland AB

Södertälje, Stockholm County, Sweden

About

Experienced pharmaceutical executive with a demonstrated history of delivering results in the pharmaceuticals industry. Strong business development professional skilled in Business Development, sales and marketing strategy, Life Sciences, Clinical Research & Market Research, M&A due diligence activities, organisational design and development. Proven record in business and people leadership - from building large teams to delivering projects and strategies in challenging environments with multiple stakeholders. Known for my ability to build strong working relationships, get to the heart of issues quickly and use this to create win-win solutions

Experience

  • Senior Consultant at FHC Undeland AB
    Dec 2012 - Present · 13 yrs 7 mos

    FHC Undeland AB, commercial input in early and late stage drug development: - Market research and analysis - Definition of Target Product Profile (TPP) - Key Opinion Leader consultation - Portfolio prioritization - Sales Forecasting - Business Development

  • Commercial Director at Orexo AB
    Dec 2006 - Nov 2012 · 6 yrs

    Responsible and accountable for: Strategic commercial input into cross functional development teams Business Development, negotiated and finalized four new licensing deals Business Alliance with existing partners

  • Global Brand Manager, Pain Control and Strategic Marketing at AstraZeneca
    Dec 1998 - Nov 2006 · 8 yrs

    o Accountable for AZ Early project network across all therapeutics areas o Responsible for the commercial input into the Global R&D Lean sigma project o Commercial lead in the analgesia EPT (Emerging Product Team) and licensing team o Commercially responsible for the TA Pain strategy plan

  • Nordic Product Manager, Neurology at sanofi-aventis
    Jul 1996 - Nov 1998 · 2 yrs 5 mos

    o Accountable for the introduction Copaxone in the Nordic region

  • Clinical Project Leader at Pharmacia
    1991 - 1996 · 5 yrs

    Accountable for the Fragmin clinical development program for unstable angina, including two multicentre studies (FRISC and FRIC), with 100 sites, in nine countries and in total 3000 patients